Just noticed another dose of FUD from Bernstein that I had previously overlooked. From your second link in #msg-57418740:
This is nonsense, of course. Once the Hatch-Waxman 30-month stay expires (which happens in a few weeks), the Copaxone patent case has no bearing on FDA approval of NVS/MNTA’s Copaxone ANDA.